Methodological advances in the discovery of novel neuroblastoma therapeutics.

Journal: Expert opinion on drug discovery
Published Date: Feb 1, 2022

Abstract

INTRODUCTION: Neuroblastoma is a cancer of the sympathetic nervous system that causes up to 15% of cancer-related deaths among children. Among the ~1,000 newly diagnosed cases per year in Europe, more than half are classified as high-risk, with a 5-year survival rate <50%. Current multimodal treatments have improved survival among these patients, but relapsed and refractory tumors remain a major therapeutic challenge. A number of new methodologies are paving the way for the development of more effective and safer therapies to ultimately improve outcomes for high-risk patients.

Authors

  • Miguel F Segura
    Pediatric Oncology and Hematology Department, Translational Research in Child and Adolescent Cancer, Vall d'Hebron Institut de Recerca (VHIR), Barcelona. Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Aroa Soriano
    Pediatric Oncology and Hematology Department, Translational Research in Child and Adolescent Cancer, Vall d'Hebron Institut de Recerca (VHIR), Barcelona. Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Josep Roma
    Pediatric Oncology and Hematology Department, Translational Research in Child and Adolescent Cancer, Vall d'Hebron Institut de Recerca (VHIR), Barcelona. Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Olga Piskareva
    Cancer Bioengineering Group, Department of Anatomy and Regenerative Medicine, RCSI University of Medicine and Health Sciences, Dublin, Ireland.
  • Carlos Jiménez
    Nephrology Department, Hospital La Paz, Madrid, Spain.
  • Ariadna Boloix
    Pediatric Oncology and Hematology Department, Translational Research in Child and Adolescent Cancer, Vall d'Hebron Institut de Recerca (VHIR), Barcelona. Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Jamie I Fletcher
    Children's Cancer Institute Australia, Lowy Cancer Research Centre, UNSW Sydney, Kensington, Australia.
  • Michelle Haber
    Children's Cancer Institute Australia, Lowy Cancer Research Centre, UNSW Sydney, Kensington, Australia.
  • Juliet C Gray
    Antibody and Vaccine Group, Centre for Cancer Immunology, University of Southampton Faculty of Medicine, Southampton, UK.
  • Leonor Cerdá-Alberich
    Biomedical Imaging Research Group (GIBI230), La Fe Health Research Institute, Av. Fernando Abril Martorell 106, Torre E, 46026, Valencia, Spain.
  • Blanca Martínez de Las Heras
    Paediatric Oncology Unit, La Fe University and Polytechnic Hospital, Av. Fernando Abril Martorell 106, Torre G, 2 Floor, 46026, Valencia, Spain.
  • Adela Cañete
    Paediatric Oncology Unit, La Fe University and Polytechnic Hospital, Av. Fernando Abril Martorell 106, Torre G, 2 Floor, 46026, Valencia, Spain.
  • Soledad Gallego
    Pediatric Oncology and Hematology Department, Translational Research in Child and Adolescent Cancer, Vall d'Hebron Institut de Recerca (VHIR), Barcelona. Universitat Autònoma de Barcelona, Bellaterra, Spain.
  • Lucas Moreno
    Pediatric Oncology and Hematology Department, Translational Research in Child and Adolescent Cancer, Vall d'Hebron Institut de Recerca (VHIR), Barcelona. Universitat Autònoma de Barcelona, Bellaterra, Spain.

Keywords

External Resources

Popular Topics
Recent Journals